<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383043</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA033364-02</org_study_id>
    <nct_id>NCT02383043</nct_id>
  </id_info>
  <brief_title>Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua A. Lile, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cocaine-use disorders continue to be a significant public health concern, yet no effective
      medications have been identified. The goal of this study is to establish a research platform
      for the development of medications for treatment of cocaine abuse and dependence. This study
      will incorporate choice self-administration procedures between drug and a non-drug
      alternative reinforcer presented during maintenance on d-amphetamine, which has been
      previously shown to reduce cocaine use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Injections of self-administered cocaine</measure>
    <time_frame>33 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Active Cocaine Users</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine choice during d-amphetamine maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine choice during placebo maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine</intervention_name>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained Release d-Amphetamine</intervention_name>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Dexedrine Spansule SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cocaine use, otherwise healthy

        Exclusion Criteria:

          -  Laboratory results outside of clinically acceptable ranges, history of or current
             serious physical or psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratory of Human Behavioral Pharmacology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Wagner, RN</last_name>
      <phone>859-257-5388</phone>
    </contact>
    <investigator>
      <last_name>Joshua Lile, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>February 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joshua A. Lile, Ph.D.</investigator_full_name>
    <investigator_title>Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
